Cardiologists and vascular surgeons were previously told they could still use the device if necessary. Now, however, the message is that they should return the product to the manufacturer.

Direct oral anticoagulants continue to be underutilized and inappropriately dosed. The American College of Cardiology hopes a new scientific statement can help address those issues and provide clinicians with an updated look at this important topic.

The recall includes a total of nearly 45,000 devices that should be returned to the manufacturer.

The deal, first announced in April, includes an upfront payment of $20 million and up to an additional $25 million based on certain milestones.

PAD patients treated with GLP-1 receptor agonists lived longer, stayed out of the hospital more and experienced fewer amputations than those given metformin.

The AMDS Hybrid Prosthesis was designed to help clinicians treat DeBakey Type 1 dissections complicated by malperfusion. It works as a complement to hemiarch replacement, preserving the native arch and making reinterventions possible if needed. 

Thousands of procedure kits used by cardiologists and cardiac surgeons are impacted by the new Class II recall. 

The newly cleared software alerts clinicians when it detects a suspected vascular occlusion.

The updated labeling comes after the devices were found to be both safe and effective for the treatment of ruptured aneurysms.